Opus Genetics, Inc.'s SEC filings document financing, governance, capital-structure and operating disclosures for a Delaware clinical-stage biopharmaceutical company developing ophthalmic gene therapies. Form 8-K reports cover senior secured notes, preferred stock private placement activity, financial results, corporate presentations and compensatory arrangements.
Proxy materials and stockholder-vote reports cover director elections, auditor ratification, say-on-pay matters and amendments affecting authorized common stock. The filings also record corporate updates related to the company's inherited retinal disease pipeline and Phentolamine Ophthalmic Solution 0.75%.
Opus Genetics entered a senior secured note purchase agreement with Oberland Capital affiliates providing for up to $155 million of non-dilutive funding, with an initial $35 million tranche expected at the April 20, 2026 closing and additional tranches tied to time-based and FDA milestones for OPGx-LCA5.
The notes mature on April 2, 2033, carry floating interest based on Term SOFR with a 3.68% floor plus margin, and feature six years of interest-only payments, partial paid-in-kind interest for the first eight quarters of each tranche, and a 50% principal amortization on the sixth anniversary of the first purchase date. Up to 10% of each purchaser’s principal may be converted into common stock at $6.72 per share.
Opus also agreed to sell 1,116,070 common shares at $4.48 per share for an aggregate $4,999,994 and grant price-protection options on additional shares if a future dilutive equity round occurs. The company reports approximately $100 million in cash including the initial note and equity funding and states this extends its runway into 2029 to support pivotal OPGx-LCA5 and OPGx-BEST1 studies and broader pipeline development.
Opus Genetics, Inc. is asking stockholders to vote at its 2026 virtual annual meeting on April 20, 2026. Investors will elect nine directors, ratify Ernst & Young, LLP as auditor for 2026, and cast an advisory vote on executive compensation.
A key proposal seeks to amend the Restated Certificate of Incorporation to increase authorized common shares from 125 million to 250 million, expanding the company’s capacity for future equity issuance. The proxy also details an independent board with separate Chair and CEO roles, fully independent key committees, and policies such as no poison pill and a prohibition on hedging by directors and officers.
Opus Genetics, Inc. Chief Operating Officer Joseph K. Schachle reported an automatic sale of 3,719 shares of common stock at $5.2501 per share. The company executed this sale to satisfy tax withholding obligations arising from a restricted stock unit vesting event, and it was not a discretionary trade by Schachle. After the transaction, he directly holds 300,781 shares of Opus Genetics common stock.
Opus Genetics, Inc. executive Amy Zaremba Rabourn, Head of Financial Quality Assurance, reported an automatic sale of 2,816 shares of common stock at $5.245 per share. The shares were sold by the company to satisfy tax withholding obligations from a restricted stock unit vesting event, and the filing states this was not a discretionary trade. After this transaction, she directly holds 190,312 shares of common stock.
Opus Genetics, Inc. Chief Executive Officer George Magrath reported an automatic sale of 24,438 shares of common stock at a weighted average price of $5.2102 per share. The shares were sold by the company to cover tax withholding obligations arising from a restricted stock unit vesting event and were not a discretionary trade by the executive. Following this tax-related transaction, Magrath directly holds 1,750,855 shares of Opus Genetics common stock.
Opus Genetics, Inc. Chief Scientific & Dev. Officer Jayagopal Ashwath reported an automatic sale of 3,719 shares of common stock at a weighted average price of $5.1213 per share. The shares were sold to cover tax withholding obligations from a restricted stock unit vesting event and were not a discretionary trade. After this transaction, he holds 516,775 shares directly.
Opus Genetics, Inc. is registering up to 7,374,632 shares of Common Stock for resale by the selling stockholders.
Those shares are issuable upon conversion of 7,374,632 shares of Series B Non‑Voting Convertible Preferred Stock and will be convertible following stockholder approval of an increase in authorized Common Stock and subject to each holder’s beneficial ownership limits.
The registration is a resale registration for the selling stockholders; the Company will not receive proceeds from resale. Shares outstanding were 71,149,045 as of March 5, 2026.
Opus Genetics, Inc. is soliciting proxies for its 2026 virtual annual meeting to be held April 20, 2026
The meeting will consider the election of nine director nominees, ratification of Ernst & Young, LLP as auditor, an advisory vote on named executive officer compensation, and a proposal to amend the Restated Certificate of Incorporation to increase authorized Common Stock from 125 million to 250 million. Shares outstanding were 71,149,045 as of March 5, 2026. The Board recommends a vote FOR all proposals and encourages stockholders to vote by mail, phone, or internet prior to the meeting.